MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: IMARC Group
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group - The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market - IMARCgroup.com
Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group

 

NewswireToday - /newswire/ - Noida, Uttar Pradesh, India, 2012/03/15 - The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market - IMARCgroup.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

IMARC Group, one of the world’s leading research and advisory firms, in its latest study “Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016” finds that driven by factors such as a large patient pool, strong biomanufacturing capabilities, absence of an Indian patent for most in-market monoclonal antibodies and an increasing prevalence of health Insurance; the market for therapeutic monoclonal antibodies in India is expected to grow at a CAGR of 27% during 2011-2016. The study, that has been undertaken using desk-based as well as qualitative primary market research provides and draws upon a comprehensive analysis of the Indian therapeutic monoclonal antibodies market.

What we have achieved in this Report
Understanding the strengths, weaknesses, opportunities and challenges in the Indian therapeutic monoclonal antibodies market
Understanding the technological considerations and regulatory factors in the Indian therapeutic monoclonal antibodies market

• Evaluation and identification of monoclonal antibodies based on the sources from which they are derived and on the targets against which they act
• Understanding the key regulations for registering, manufacturing and importing therapeutic monoclonal antibodies in India
Evaluating the patent details of all globally marketed monoclonal antibodies in India, US and Europe
• Identifying the patentee name and patent numbers of all in-market monoclonal antibodies in India, US and Europe
• Identifying the monoclonal antibodies that are patent protected in India, US and Europe and those that are not
• Estimating the patent expiries of various monoclonal antibodies in India, US and Europe
Comprehensive situation analysis of the Indian therapeutic antibodies market
• Analyzing current and future sales of monoclonal antibodies in India
• Identifying all globally launched monoclonal antibodies and understanding their performance and launch status in India
• Analyzing the global and Indian monoclonal antibodies market by Indication
• Evaluation of the top selling monoclonal antibodies
• Key biosimilar antibody development programmes in India and abroad

Key Questions Answered in this Report

• What is the current size and growth of the Indian therapeutic monoclonal antibodies market?
• What are the most popular indications for which therapeutic monoclonal antibodies are prescribed in India?
• Who are the key players operating in the Indian therapeutic monoclonal antibodies market?
• Which are the top selling therapeutic monoclonal antibodies in India?
• What are the strengths, weaknesses, opportunities and threats in the Indian therapeutic monoclonal antibodies market?
• What are the key requirements to launch a therapeutic monoclonal antibody in India?
• What is the patent position of various in-market therapeutic monoclonal antibodies in India?
• Which therapeutic monoclonal antibodies are protected by a patent in India and when will their patents expire?
• Which therapeutic monoclonal antibodies already have biosimilars available in India?
• What are the key biosimilar monoclonal antibody development programmes in India?

To obtain the complete report, please contact

IMARC Group Asia
E: apac[.]imarcgroup.com

IMARC Group North America
E: america[.]imarcgroup.com - P: +1-631-791-1145.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IMARC Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Indian Therapeutic Monoclonal Antibodies Market to Grow at a CAGR of 27% During 2011-2016 Finds IMARC Group

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Krishna Sharma - IMARCgroup.com 
+91 12 04155099 press[.]imarcgroup.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IMARC Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IMARC Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  Digital45 | Studio45 IT Services (P) Ltd





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)